Melissa Layman Net Worth

The estimated Net Worth of Melissa Layman is at least $1.04 million dollars as of 15 March 2021. Ms. Layman owns over 4,520 units of Flexion Therapeutics Inc stock worth over $955,356 and over the last 5 years she sold FLXN stock worth over $86,267. In addition, she makes $0 as Chief Commercial Officer at Flexion Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Layman FLXN stock SEC Form 4 insiders trading

Melissa has made over 2 trades of the Flexion Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 4,520 units of FLXN stock worth $53,336 on 15 March 2021.

The largest trade she's ever made was selling 4,520 units of Flexion Therapeutics Inc stock on 15 March 2021 worth over $53,336. On average, Melissa trades about 1,429 units every 9 days since 2020. As of 15 March 2021 she still owns at least 103,956 units of Flexion Therapeutics Inc stock.

You can see the complete history of Ms. Layman stock trades at the bottom of the page.

Melissa Layman biography

Melissa Layman serves as Chief Commercial Officer of the Company. Before joining Flexion, Ms. Layman served as Vice President, Global Sales and Marketing at Lantheus Medical Imaging where she was a member of the executive leadership team. During her nearly 10-year tenure, she was responsible for global sales, marketing, communications, health policy, pricing and reimbursement, commercial development and international operations. Prior to Lantheus, she served as Executive Marketing Director at Forest Laboratories (now Allergan), where she led the cardiovascular franchise through the successful launch of its lead product, Bystolic. Ms. Layman also held senior marketing positions at Altus Pharmaceuticals (now Vertex) and Sepracor (now Sunovion), where she launched Xopenex MDI and Lunesta, building and integrating the market access function across the business. She began her career with TAP Pharmaceuticals (now Takeda Oncology) where her positions ranged from sales representative to National Marketing Director, Gastroenterology and Oncology. Ms. Layman holds a B.A. from Ithaca College and an executive M.B.A. from the Kellogg School of Management at Northwestern University.

How old is Melissa Layman?

Melissa Layman is 51, she's been the Chief Commercial Officer of Flexion Therapeutics Inc since 2020. There are 13 older and 3 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.

What's Melissa Layman's mailing address?

Melissa's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.

Insiders trading at Flexion Therapeutics Inc

Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon et Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.

What does Flexion Therapeutics Inc do?

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.

Complete history of Ms. Layman stock trades at Flexion Therapeutics Inc

Flexion Therapeutics Inc executives and stock owners

Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael Clayman,
  President, Chief Executive Officer, Director
• David Arkowitz,
  Chief Financial Officer
• Scott Kelley,
  Chief Medical Officer
• Mark Levine,
  General Counsel and Corporate Secretary
• Dr. Neil Bodick,
  Consultant
• Patrick Mahaffy,
  Independent Chairman of the Board
• Sandesh Mahatme,
  Independent Director
• Samuel Colella,
  Independent Director
• Alan Milinazzo,
  Independent Director
• Mark Stejbach,
  Independent Director
• C. Ann Merrifield,
  Independent Director
• Scott Canute,
  Independent Director
• Heath Lukatch,
  Independent Director
• Scott Young,
  IR Contact Officer
• Elizabeth Kwo,
  Director
• Christina Willwerth,
  Chief Strategy Officer
• Kerry Wentworth,
  Chief Regulatory Officer
• Melissa Layman,
  Chief Commercial Officer
• John Magee,
  VP of Sales
• Carolyn Beaty Scimemi,
  VP, Legal Affairs & Chief Compliance Officer
• David A. Arkowitz M.B.A.,
  Chief Financial Officer
• Ventures Iii, Llc Versant V...,
  
• Yamo Deniz,
  Chief Medical Officer
• Frederick W Driscoll,
  Chief Financial Officer
• Barbara N Bolzon Bradley J ...,
  
• William T. Andrews,
  Chief Medical Officer
• Utpal Koppikar,
  Director
• Neil Bodick,
  Chief Scientific Officer
• Ventures Ii Lp5 Am Co Inves...,
  
• Holdings A/S Novo,
  10% owner
• Partners Sas Sofinnova,
  10% owner
• Venture Capital Iii, L.P.Bo...,
  
• Venture Capital Iii, L.P.Ve...,
  
• Rafael Tordjman,
  Director
• Andrew J. Schwab,
  Director
• Bradley J Ph D Bolzon,
  Director
• Venture Capital Iii, L.P.Ve...,
  
• Inc Pfizer,
  10% owner
• Management, Llc Newtyn,
  10% owner
• Adam Muzikant,
  Chief Business Officer